신장 이식을 받는 환자의 몸이 이식을 받아들이도록 돕기 위한 시플리주맙과 토끼 항흉선세포 글로불린의 비교 연구 (MODERNIZE1)
타크로리무스, 마이코페놀산 및 코르티코스테로이드를 포함한 표준 치료 면역억제 요법을 받으며 유도 요법이 필요한 신장 이식 수혜자에서 시플리주맙(TCD601)을 토끼 항-흉선 글로불린과 비교하는 2b상 무작위 다기관 이중 맹검 용량 탐색 능동 대조 연구
The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease. The main questions it aims to answer are:
How many adverse events do participants receiving two different doses of siplizumab have compared to rabbit anti-thymocyte globulin (rATG)?
How many participants successfully keep their kidney transplant after receiving siplizumab or rATG? This will be calculated as those participants that did not: die; have their kidney fail to work properly (graft loss); their body rejects their transplant (tissue sample (biopsy)-proven acute rejection: BPAR); or who were lost to follow-up.
How does the body respond to siplizumab after dosing at each of the 2 dose levels?
How does siplizumab work in the body compared to rATG?
Selected participants will be divided into 3 groups. In 2 of the groups, participants will be given siplizumab at one of the two study medicine doses. Participants in the third group will be given rATG. All participants will take the usual anti-rejection medicines given before, during, and after a kidney transplant. All participants will also be given medicines before the study drug to lower the risk of reactions, and medicines used to prevent or treat infections after the transplant.
Participants will be asked to provide their medical history at the first visit at the study site where you will have your kidney transplant. At the first visit and other visits participants will be asked to provide their medication history, have a physical exam, check vital signs, have blood drawn for tests, and have non-invasive tests that record the electrical activity of your heart (ECG) and blood draws.
Participants will be monitored for 12 months after transplant surgery.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Approximately 120 renal transplant candidates requiring induction therapy will be enrolled 1:1:1 to receive 1 of 2 dose levels of siplizumab or to the comparator rATG.
Randomization will be stratified by donor status (living vs donation after brain death vs donation after cardiac death) to ensure similar proportions of donor types in each study arm. All participants will also receive:
- A triple regimen (TAC, MPA, and CS) of background immunosuppressive therapy for the duration of the study.
- Premedication prior to study treatment infusions.
- Infection prophylaxis
This clinical trial will evaluate the safety of an anti-cluster of differentiation 2 (CD2) monoclonal antibody, siplizumab, compared to rATG as induction therapy in renal transplant recipients.
Following hospital discharge, participants will undergo assessments and procedures as indicated in the protocol through Month 12 or EOS, unless more frequent visits are required per local SoC or for laboratory specimen collection.
Safety assessments will include physical examinations, ECGs, vital signs, viral surveillance and monitoring, standard clinical laboratory evaluations completed centrally (hematology, clinical chemistry, urinalysis), and AE/SAE monitoring.
Final analysis will be performed when all participants have completed 12-month follow-up visits post-transplant or have otherwise ended the trial. This analysis will be performed to evaluate the safety of siplizumab at 2 dose levels compared to rATG.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
California
-
Los Angeles, California, 미국, 90033
- 모병
- Keck Hospital of the University of Southern California
-
연락하다:
- Melissa Ramos
- 전화번호: 323-442-7983
- 이메일: Melissa.Ramos@med.usc.edu
-
Los Angeles, California, 미국, 90095
- 모병
- University of California - Los Angeles, Connie Frank Kidney Transplant Center
-
연락하다:
- Suphamai Bunnapradist, MD
- 전화번호: 310-794-8516
- 이메일: bunnapradist@mednet.ucla.edu
-
Sacramento, California, 미국, 95817
- 모병
- UC Davis Medical Center
-
연락하다:
- Timothy Huynh, Clinical Research Coordinator
- 전화번호: 916-703-4471
- 이메일: ttihuynh@health.ucdavis.edu
-
-
Florida
-
Tampa, Florida, 미국, 33606
- 모병
- Tampa General Hospital
-
연락하다:
- Jennifer Schmidt, BSN, RN
- 전화번호: 813-844-7041
- 이메일: jenniferanilsen@tgh.org
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- 모병
- Emory University Hospital
-
연락하다:
- Emily Temponi, Study Coordinator
- 전화번호: 404-712-1114
- 이메일: emily.k.temponi@emory.edu
-
-
Kansas
-
Kansas City, Kansas, 미국, 66160
- 모병
- University of Kansas Hospital
-
연락하다:
- Adam Schooley, MA, CCRP
- 전화번호: 913-588-1699
- 이메일: aschooley@kumc.edu
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40536
- 모병
- University of Kentucky Healthcare
-
연락하다:
- Malay Shah, MD
- 전화번호: 859-338-1615
- 이메일: malay.shah@uky.edu
-
-
Louisiana
-
Metairie, Louisiana, 미국, 70006
- 모병
- Tulane Medical Center
-
연락하다:
- Nicole Jackson
- 전화번호: 504-988-5344
- 이메일: njackson3@tulane.edu
-
-
Massachusetts
-
Worcester, Massachusetts, 미국, 01655
- 모병
- UMass Chan Medical Center
-
연락하다:
- Anil Chandraker, MD
- 전화번호: 508-334-7087
- 이메일: anil.chandraker4@umassmed.edu
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- 모병
- University of Michigan - Michigan Medicine
-
연락하다:
- Nerissa Reister, Clinical Research Coordinator
- 전화번호: 734-763-5718
- 이메일: naflow@med.umich.edu
-
Detroit, Michigan, 미국, 48202
- 모병
- Henry Ford Health
-
연락하다:
- Matthew Callaghan
- 전화번호: 313-916-4596
- 이메일: mcallag2@hfhs.org
-
-
New Jersey
-
Livingston, New Jersey, 미국, 07039
- 모병
- Cooperman Barnabus Medical Center
-
연락하다:
- Jayrol Mock, APN
- 전화번호: 973-322-2339
- 이메일: Jayrol.Mock2@rwjbh.org
-
-
New York
-
New York, New York, 미국, 10032
- 모병
- New York Presbyterian - Columbia University Irving Medical School
-
수석 연구원:
- Lloyd Ratner, MD
-
연락하다:
- Angela Sanchez, CRC
- 전화번호: 212-305-3839
- 이메일: as5546@cumc.columbia.edu
-
연락하다:
- Theresa Lukose, Research Director
- 전화번호: 212-305-3839
- 이메일: tt2103@cumc.columbia.edu
-
New York, New York, 미국, 10065
- 모병
- New York Presbyterian - Weill Cornell Medical Center
-
연락하다:
- Jennifer Lee
- 전화번호: 212-746-0192
- 이메일: jel9109@nyp.org
-
연락하다:
- Meredith Aull
- 전화번호: 212-746-5330
- 이메일: mea9008@med.cornell.edu
-
-
North Carolina
-
Durham, North Carolina, 미국, 27710
- 모병
- Duke University Medical Center
-
연락하다:
- Lynnette Moats
- 전화번호: 919-949-6574
- 이메일: lynnette.moats@duke.edu
-
-
Texas
-
Dallas, Texas, 미국, 75390
- 모병
- University of Texas Southwestern Medical Center
-
연락하다:
- David Wojciechowski, DO
- 전화번호: 214-645-7846
- 이메일: David.Wojciechowski@UTSouthwestern.edu
-
-
Virginia
-
Falls Church, Virginia, 미국, 22042
- 모병
- Inova Fairfax Hospital
-
연락하다:
- Alma Khan, MSN, CCRC
- 전화번호: 703-776-5912
- 이메일: Alma.Khan2@inova.org
-
Richmond, Virginia, 미국, 23298
- 모병
- Virginia Commonwealth University Health
-
연락하다:
- Meron Zeleke
- 전화번호: 804-628-4969
- 이메일: Meron.Zeleke@vcuhealth.org
-
-
Washington
-
Seattle, Washington, 미국, 98195
- 모병
- University of Washington Medical Center
-
연락하다:
- Belinda Pan, Research Coordinator
- 전화번호: 206-598-1562
- 이메일: bcpan@uw.edu
-
-
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, 브라질, 30150-320
- 모병
- Santa Casa Demisericordia de Belo Horizonte
-
연락하다:
- Pedro Macedo de Souza
- 전화번호: +55 (31) 3238-8975
- 이메일: pmacedosouza@gmail.com
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, 브라질, 90035-903
- 모병
- Hospital de Clinicas de Porto Alegre
-
연락하다:
- Research Coordinator
- 전화번호: +55 51 3359-6253
- 이메일: l-genetica@hcpa.edu.br
-
Porto Alegre, Rio Grande do Sul, 브라질, 90020-090
- 모병
- Santa Casa de Misericordia de Porto Alegre - Hospital Dom Vincente Scherer
-
연락하다:
- Research Coordinator
- 전화번호: +55 51 3214-8640
- 이메일: pesquisa@santacasa.org.br
-
-
São Paulo
-
São José do Rio Preto, São Paulo, 브라질, 15090-000
- 모병
- Fundação Faculdade Regional de Medicina de São José do Rio Preto - Centro Integrado de Pesquisa
-
연락하다:
- Research Coordinator
- 전화번호: +55 (17) 3201-5054
- 이메일: osvaldo.junior@centrodepesquisacip.com.br
-
São Paulo, São Paulo, 브라질, 04038-002
- 모병
- Fundação Oswaldo Ramos - Hospital do Rim (HRIM)
-
연락하다:
- Research Coordinator
- 전화번호: +55 (11) 5087-8110
- 이메일: hospital@hrim.com.br
-
-
-
-
-
Barcelona, 스페인, 08035
- 모병
- Hospital Universitari Vall D'Hebron
-
연락하다:
- Study Coordinator
- 전화번호: +34 932746000
- 이메일: assajos.nefrologia@vhir.org
-
Córdoba, 스페인, 14004
- 모병
- Hospital Universitario Reina Sofía
-
연락하다:
- Álvaro Torres, MD
- 전화번호: +34 957010440
- 이메일: nefro.hrs.sspa@juntadeandalucia.es
-
Málaga, 스페인, 29010
- 모병
- Hospital Universitario Regional de Malaga
-
연락하다:
- Study Coordinator
- 전화번호: +34 951291174
- 이메일: estudios.clinicos@ibima.eu
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Recipients of a renal allograft from a non-HLA identical living or deceased donor.
- Recipients of a kidney with a cold ischemia time < 30 hours; hypothermic machine perfusion within the same timeframe is acceptable.
- Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, must agree to use highly effective methods of contraception.
Exclusion Criteria:
- Transplant recipients seronegative for EBV.
- Transplant recipients receiving a kidney from a non-heart beating donor (ie, DCD) whose organ is retrieved from an uncontrolled DCD or whose donor age > 55 years of age.
- Multi-organ transplant recipients (eg, kidney-pancreas, organ other than kidney), dual-kidney transplant recipients, recipients with more than one prior kidney transplant, or hematopoietic stem cell transplantation recipients.
- Presence of current or historical DSA via single-antigen bead assay or local SoC. The MFI cut-off value used to determine the presence of DSA will be defined as per the institutional SoC. Results within 3 months prior to transplant are acceptable.
- Crossmatch positive (isolated positive B cell crossmatches are not an exclusion criterion).
- ABO-incompatible recipient.
- Administration of complement inhibitor therapy within 6 months prior to the transplant, or likely to require treatment with complement inhibitor therapy during the study.
- Participants receiving immunosuppressive therapies prior to transplant for pre-existing conditions must be candidates for the protocol-defined regimen.
- History of malignancy of any organ system, except for localized excised non-melanomatous skin lesions or carcinoma in situ of the cervix.
- Seropositive for human immunodeficiency virus or hepatitis B surface antigen. Participants who are seropositive for hepatitis C virus (HCV) are excluded without proof of sustained viral response after anti-HCV treatment.
- Recipient of a kidney from a donor who tests positive for human immunodeficiency virus or hepatitis B surface antigen/hepatitis B core protein.
- History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (eg, siplizumab, rATG, TAC, MPA derivatives, CS).
- Evidence of active tuberculosis (TB) infection (participants with a history of latent TB may become eligible after treatment with anti-TB therapy according to national guidelines).
- Participants with severe systemic infection(s), at the time of screening or within 2 weeks prior to randomization
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: 저용량 시플리주맙
|
A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class
다른 이름들:
|
|
실험적: 고용량 시플리주맙
|
A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class
다른 이름들:
|
|
활성 비교기: 토끼 항 흉선 세포 글로불린
|
An anti-human thymocyte immunoglobulin preparation made of purified polyclonal antibodies derived from rabbits
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Assessment of the safety of 2 dose levels of siplizumab versus rATG.
기간: 12 months
|
Number and percentage of participants at 12 months post-transplant experiencing adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs). |
12 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
기간: 12 months
|
|
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
기간: 12 months
|
• Grade of BPAR. |
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
기간: 12 months
|
• Severity of BPAR. |
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
기간: 12 months
|
|
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
기간: 12 months
|
|
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
기간: 12 months
|
• Number of participants requiring for-cause renal allograft biopsy assessments over 12 months post-transplant. |
12 months
|
|
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
기간: 12 weeks
|
Siplizumab Cmax (maximum blood concentration) over 12 weeks post-transplant. |
12 weeks
|
|
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
기간: 12 weeks
|
Siplizumab AUC (area under the concentration-time curve) over 12 weeks post-transplant. |
12 weeks
|
|
Assessment of the pharmacodynamics (PD) of 2 dose levels of siplizumab versus rATG.
기간: 12 months
|
Depletion and recovery of lymphocyte count by subset (total lymphocytes; CD3+, CD4+, and CD8+ T cells; CD19+ B cells; CD56+ NK cells) over 12 months post-transplant. |
12 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- TCD601B205
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .